Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Characterization of Tumor Proteases that Reduce Reovirus Oncolysis

FY 2018-19

Summary
Reovirus is an oncolytic (cancer-killing) virus undergoing clinical trials against various cancers. However, to be an effective treatment, reovirus must overcome unique factors found in the tumor microenvironment (TME). The TME is enriched in a class of enzymes known as metalloproteases (MPs). We found that treating reovirus with MPs extracted from mouse tumors (tumor extract; TE) resulted in a loss of infectivity, suggesting that the TME contains factors which inactivate reovirus. We hypothesize that protease levels in specific cancer patients will alter the efficacy of reovirus therapy. If we can determine the precise proteases that inactivate reovirus, and develop protease resistant reovirus variants, we hope we can advance personalized treatments with reovirus. To better understand and overcome TME proteases which inactivate reovirus, we propose the following objectives: (1) The MPs will be purified from the TE, and analyzed by mass spectrometry, allowing us to determine the likely identity of the MP. Purified proteases of the best candidates will be purchased and assessed for their effect on reovirus. (2) We've found that human cancer cell lines also secrete proteases that inactivate reovirus. We will assess the prevalence of the MP identified in aim 1 in a variety of cancer cell lines to determine if the MP is cancer type specific. (3) The specific site on reovirus which MPs target will be determined using N-terminal sequencing. This will allow us to generate viruses with mutations in the target site, which I predict will be resistant to MP inactivation. (4) These mutant viruses from aim 3 will be tested for oncolytic activity relative to wild-type reovirus. I hope my findings help improve the potency of reovirus as an oncolytic therapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406472
Name
Fernandes Jason P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Tumor Proteases that Reduce Reovirus Oncolysis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biochemistry; Breast Cancer; Experimental Oncology; Metalloprotease; Oncolytic Virology; Recombinant Viruses; Reovirus; Structural Virology; Tumor Microenvironment; Tumor Proteases
Abstract
Reovirus is an oncolytic (cancer-killing) virus undergoing clinical trials against various cancers. However, to be an effective treatment, reovirus must overcome unique factors found in the tumor microenvironment (TME). The TME is enriched in a class of enzymes known as metalloproteases (MPs). We found that treating reovirus with MPs extracted from mouse tumors (tumor extract; TE) resulted in a loss of infectivity, suggesting that the TME contains factors which inactivate reovirus. We hypothesize that protease levels in specific cancer patients will alter the efficacy of reovirus therapy. If we can determine the precise proteases that inactivate reovirus, and develop protease resistant reovirus variants, we hope we can advance personalized treatments with reovirus. To better understand and overcome TME proteases which inactivate reovirus, we propose the following objectives: (1) The MPs will be purified from the TE, and analyzed by mass spectrometry, allowing us to determine the likely identity of the MP. Purified proteases of the best candidates will be purchased and assessed for their effect on reovirus. (2) We've found that human cancer cell lines also secrete proteases that inactivate reovirus. We will assess the prevalence of the MP identified in aim 1 in a variety of cancer cell lines to determine if the MP is cancer type specific. (3) The specific site on reovirus which MPs target will be determined using N-terminal sequencing. This will allow us to generate viruses with mutations in the target site, which I predict will be resistant to MP inactivation. (4) These mutant viruses from aim 3 will be tested for oncolytic activity relative to wild-type reovirus. I hope my findings help improve the potency of reovirus as an oncolytic therapy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fernandes, Jason P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~